A detailed history of Creative Planning transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Creative Planning holds 13,671 shares of CRSP stock, worth $654,567. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,671
Previous 14,750 7.32%
Holding current value
$654,567
Previous $796,000 19.35%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

SELL
$44.62 - $62.75 $48,144 - $67,707
-1,079 Reduced 7.32%
13,671 $642,000
Q2 2024

Aug 15, 2024

BUY
$51.17 - $68.18 $23,333 - $31,090
456 Added 3.19%
14,750 $796,000
Q1 2024

May 10, 2024

BUY
$60.67 - $89.12 $29,364 - $43,134
484 Added 3.5%
14,294 $974,000
Q4 2023

Feb 14, 2024

SELL
$38.62 - $72.18 $44,026 - $82,285
-1,140 Reduced 7.63%
13,810 $864,000
Q3 2023

Nov 16, 2023

BUY
$45.39 - $59.0 $258,813 - $336,418
5,702 Added 61.66%
14,950 $678,000
Q2 2023

Jul 21, 2023

SELL
$43.47 - $67.77 $6,390 - $9,962
-147 Reduced 1.56%
9,248 $519,000
Q1 2023

May 15, 2023

SELL
$41.0 - $56.12 $98,400 - $134,688
-2,400 Reduced 20.35%
9,395 $424,000
Q4 2022

Feb 10, 2023

SELL
$39.19 - $65.67 $7,132 - $11,951
-182 Reduced 1.52%
11,795 $479,000
Q3 2022

Nov 03, 2022

BUY
$61.1 - $83.78 $48,391 - $66,353
792 Added 7.08%
11,977 $783,000
Q2 2022

Aug 15, 2022

BUY
$43.23 - $73.83 $39,079 - $66,742
904 Added 8.79%
11,185 $680,000
Q1 2022

May 16, 2022

BUY
$53.19 - $79.24 $26,116 - $38,906
491 Added 5.02%
10,281 $645,000
Q4 2021

Feb 11, 2022

SELL
$70.09 - $111.29 $166,814 - $264,870
-2,380 Reduced 19.56%
9,790 $742,000
Q3 2021

Nov 10, 2021

BUY
$110.2 - $156.64 $302,168 - $429,506
2,742 Added 29.08%
12,170 $1.36 Million
Q2 2021

Aug 04, 2021

SELL
$100.84 - $161.89 $395,696 - $635,256
-3,924 Reduced 29.39%
9,428 $1.53 Million
Q1 2021

Apr 30, 2021

BUY
$110.72 - $210.04 $166,301 - $315,480
1,502 Added 12.68%
13,352 $1.63 Million
Q4 2020

Jan 29, 2021

BUY
$79.67 - $173.23 $110,820 - $240,962
1,391 Added 13.3%
11,850 $1.81 Million
Q3 2020

Nov 05, 2020

BUY
$78.5 - $100.64 $489,840 - $627,993
6,240 Added 147.9%
10,459 $875,000
Q2 2020

Jul 23, 2020

SELL
$38.5 - $76.05 $320,204 - $632,507
-8,317 Reduced 66.34%
4,219 $310,000
Q1 2020

May 05, 2020

SELL
$33.68 - $62.53 $103,330 - $191,842
-3,068 Reduced 19.66%
12,536 $532,000
Q4 2019

Jan 30, 2020

BUY
$36.68 - $73.13 $45,043 - $89,803
1,228 Added 8.54%
15,604 $950,000
Q3 2019

Nov 01, 2019

SELL
$40.99 - $52.56 $22,913 - $29,381
-559 Reduced 3.74%
14,376 $589,000
Q2 2019

Jul 26, 2019

SELL
$35.45 - $48.2 $19,532 - $26,558
-551 Reduced 3.56%
14,935 $703,000
Q1 2019

Apr 24, 2019

BUY
$28.02 - $40.87 $19,473 - $28,404
695 Added 4.7%
15,486 $553,000
Q4 2018

Feb 01, 2019

BUY
$22.73 - $42.34 $18,797 - $35,015
827 Added 5.92%
14,791 $423,000
Q3 2018

Oct 25, 2018

BUY
$44.35 - $65.71 $619,303 - $917,574
13,964 New
13,964 $619,000
Q1 2018

Apr 18, 2018

SELL
$23.52 - $58.17 $243,902 - $603,222
-10,370 Closed
0 $0
Q4 2017

Jan 17, 2018

BUY
$16.95 - $23.48 $175,771 - $243,487
10,370
10,370 $243,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.74B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.